Knight Therapeutics (TSE:GUD) will be issuing its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of C$0.02 per share for the quarter.
Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, May 9th. The company reported C$0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of C$0.03 by C$0.01. The company had revenue of C$2.96 million during the quarter, compared to analyst estimates of C$3.06 million.
Shares of GUD traded down C$0.14 during mid-day trading on Tuesday, hitting C$7.39. The company had a trading volume of 165,654 shares, compared to its average volume of 328,591. The business has a 50-day moving average of C$7.56. The company has a current ratio of 32.29, a quick ratio of 31.73 and a debt-to-equity ratio of 0.10. Knight Therapeutics has a 1-year low of C$7.10 and a 1-year high of C$8.72. The company has a market cap of $1.08 billion and a PE ratio of 47.37.
Separately, Raymond James reissued an “outperform” rating and issued a C$10.25 target price on shares of Knight Therapeutics in a research report on Thursday, July 18th.
In other Knight Therapeutics news, Director Robert Nathaniel Lande purchased 20,000 shares of Knight Therapeutics stock in a transaction on Thursday, July 11th. The shares were purchased at an average cost of C$7.52 per share, with a total value of C$150,300.00. Following the completion of the transaction, the director now directly owns 45,392 shares in the company, valued at approximately C$341,120.88. Also, insider Long Zone Holdings Inc. purchased 12,000 shares of Knight Therapeutics stock in a transaction on Friday, June 21st. The shares were acquired at an average cost of C$7.59 per share, for a total transaction of C$91,080.00. Following the completion of the transaction, the insider now owns 21,633,433 shares of the company’s stock, valued at C$164,197,756.47. Insiders purchased 42,000 shares of company stock worth $315,280 over the last three months.
About Knight Therapeutics
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Recommended Story: Price-Sales Ratio
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.